To determine if IGIV3I Grifols 10% is a consistently effective treatment in patients diagnosed with immune thrombocytopenic purpura with respect to:~Increase of platelet count ≥ 50x10^9/L (primary objective).~Time taken for the platelet count to reach ≥ 50x10^9/L.~The length of time the platelet count remains ≥ 50x10^9/L.~The maximum platelet level.~Regression of bleeding episodes during the first 10 or 14 days.~To determine if IGIV3I Grifols 10% is safe with respect to:~Nature, severity and frequency of adverse reactions during and after infusions by percentage of subjects and percentage of infusions.
The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.